CA2957415C - Anti-ceramide antibodies - Google Patents

Anti-ceramide antibodies Download PDF

Info

Publication number
CA2957415C
CA2957415C CA2957415A CA2957415A CA2957415C CA 2957415 C CA2957415 C CA 2957415C CA 2957415 A CA2957415 A CA 2957415A CA 2957415 A CA2957415 A CA 2957415A CA 2957415 C CA2957415 C CA 2957415C
Authority
CA
Canada
Prior art keywords
binding fragment
antigen
antibody
ceramide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2957415A
Other languages
English (en)
French (fr)
Other versions
CA2957415A1 (en
Inventor
Jimmy Rotolo
Richard Kolesnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceramide Therapeutics
Memorial Sloan Kettering Cancer Center
Original Assignee
Ceramide Therapeutics
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramide Therapeutics, Memorial Sloan Kettering Cancer Center filed Critical Ceramide Therapeutics
Publication of CA2957415A1 publication Critical patent/CA2957415A1/en
Application granted granted Critical
Publication of CA2957415C publication Critical patent/CA2957415C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2957415A 2014-08-07 2015-08-07 Anti-ceramide antibodies Active CA2957415C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
US62/034,453 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
CA2957415A1 CA2957415A1 (en) 2016-02-11
CA2957415C true CA2957415C (en) 2021-07-13

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2957415A Active CA2957415C (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Country Status (12)

Country Link
US (4) US10450385B2 (https=)
EP (2) EP4681733A3 (https=)
JP (1) JP6670297B2 (https=)
KR (1) KR102296416B1 (https=)
CN (1) CN107074949B (https=)
AU (1) AU2015300902B2 (https=)
CA (1) CA2957415C (https=)
IL (1) IL250374B (https=)
MX (1) MX391141B (https=)
RU (1) RU2717651C2 (https=)
SG (1) SG11201700787XA (https=)
WO (1) WO2016022883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2020231629A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
JP7623706B2 (ja) * 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
JP5924863B2 (ja) * 2007-05-06 2016-05-25 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
KR101256351B1 (ko) 2011-11-22 2013-04-19 김석진 필터 삽입공을 갖는 카메라 후드
WO2013125654A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
AU2013266069B2 (en) * 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体

Also Published As

Publication number Publication date
US20230416409A1 (en) 2023-12-28
EP3177650A4 (en) 2018-01-03
JP2017527544A (ja) 2017-09-21
JP6670297B2 (ja) 2020-03-18
US20250197524A1 (en) 2025-06-19
IL250374B (en) 2021-04-29
AU2015300902A1 (en) 2017-03-02
RU2717651C2 (ru) 2020-03-24
MX391141B (es) 2025-03-21
US20190389970A1 (en) 2019-12-26
RU2017105596A (ru) 2018-09-07
CN107074949A (zh) 2017-08-18
EP3177650A1 (en) 2017-06-14
US20170335014A1 (en) 2017-11-23
MX2017001686A (es) 2017-09-01
CA2957415A1 (en) 2016-02-11
NZ728981A (en) 2024-03-22
AU2015300902B2 (en) 2020-05-28
EP4681733A3 (en) 2026-05-06
US10450385B2 (en) 2019-10-22
KR102296416B1 (ko) 2021-09-01
IL250374A0 (en) 2017-03-30
SG11201700787XA (en) 2017-02-27
RU2017105596A3 (https=) 2019-04-17
BR112017002433A2 (pt) 2017-11-28
EP4681733A2 (en) 2026-01-21
KR20170066327A (ko) 2017-06-14
CN107074949B (zh) 2021-06-15
EP3177650B1 (en) 2025-11-05
WO2016022883A1 (en) 2016-02-11
US11447572B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
US20250197524A1 (en) Anti-ceramide antibodies
US20250145699A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US20240174729A1 (en) High affinity pd-1 agents and methods of use
US20250051451A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
TWI801862B (zh) 抗ｔｉｇｉｔ的抗體、其製備方法和應用
CA3032783A1 (en) Antibody to programmed cell death 1 (pd-1) and use thereof
JP6872756B2 (ja) 抗Ｍｙｌ９抗体
WO2022099126A1 (en) Anti-psma antibodies and methods of use
US8470325B2 (en) Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
EP4253424A1 (en) Bispecific antibody and use thereof
BR112017002433B1 (pt) Anticorpos anticeramida
US20240199735A1 (en) Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
CA2968330C (en) Humanized anti-trop-2 monoclonal antibodies and uses thereof
TW202613175A (zh) Cdh3結合蛋白及其用途
CA3203732A1 (en) Anti-survivin antibodies for treatment of autoimmune diseases
CA2968330A1 (en) Humanized anti-trop-2 monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200805

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250617

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250617